467 results about "After treatment" patented technology

The invention belongs to the technical field of tunnel construction geological disaster prevention and control, and discloses a multi-source data fused refined treatment decision-making method for a complex stratum disaster source, which comprises the following steps: collecting and fusing multi-source geological data, and constructing a three-dimensional geological model; generating a disaster source risk dynamic assessment and treatment scheme; based on a fluid-solid coupling similarity theory, verifying the preliminary treatment scheme by adopting a physical model test, and determining an optimal treatment scheme; the optimal treatment scheme is executed, and the treatment process is dynamically regulated and controlled; after treatment, the treatment effect is evaluated through posterior data, and the effect data is fed back to the three-dimensional geologic model and the knowledge base, so that the dynamic updating of the model and the self-learning of the decision-making system are realized. By the adoption of the treatment decision method, the problems that a traditional method depends on experience, information is one-sided, and treatment is extensive are solved, advanced accurate forecasting and refined and personalized treatment of complex stratum disaster sources are achieved, and the safety and efficiency of tunnel construction are remarkably improved.

The invention relates to the technical field of medical data analysis, in particular to a brain tumor curative effect analysis system which comprises a tumor data sensing layer for collecting multi-department diagnosis and treatment data, tumor image data and patient pathology monitoring data; the tumor feature processing center extracts data features, correlates data and core features before and after treatment through an attention mechanism, and generates a tumor complete-cycle unified feature map; the therapeutic effect dynamic analysis unit evaluates the therapeutic effect in stages, and outputs a therapeutic effect index and a recurrence risk value through a self-supervised model; the dynamic adaptation decision module is used for generating personalized treatment adjustment suggestions based on the dynamic change of the blood brain barrier in combination with the curative effect index, the recurrence risk value and the multi-omics characteristics of the patient; and the AI multi-department consultation unit automatically matches similar cases with field expert suggestions, and formulates a target diagnosis and treatment scheme based on a visual platform and multi-department doctor collaborative consultation in combination with personalized treatment adjustment suggestions. Therefore, the problems of lagging effect evaluation, insufficient diagnosis and treatment suggestions and the like in the prior art are solved.

The present invention provides compositions comprising one or more ACAT inhibitors and one or more GLP-1 receptor agonists (GLP-1 RAs). The combination therapy reduces side effects associated with high-dose GLP-1 RA monotherapy and provides durable management of weight loss by suppressing rebound of body weight, blood glucose, and cholesterol levels after treatment.

The invention belongs to the technical field of medical imaging, and relates to a method for predicting complete pathologic remission of head and neck squamous cell carcinoma and related equipment. The method comprises the following steps: respectively inputting a T1W sequence image before treatment, a T1W sequence image after treatment, a T2W sequence image before treatment and a T2W sequence image after treatment into an MR I multi-time sequence fusion module for decoupling feature extraction operation; inputting the time sequence fused T1W sequence MR I time sequence decoupling feature data and the time sequence fused T2W sequence MR I time sequence decoupling feature data into an MR I multi-sequence fusion module to carry out multi-sequence fusion operation; inputting the WSI image into a WSI feature extraction module to carry out WSI feature extraction operation; the MRI multi-sequence fusion feature data and the WSI feature data are input to an MRI-WSI multi-modal fusion module for cross fusion operation; and performing pCR prediction operation on the MRI-WSI cross fusion feature data according to a convolutional neural network and a multi-layer perceptron to obtain a pCR prediction result. The method can be independently competent for a multi-factor prediction task of pCR.

The invention discloses a sugar chain marker combination for predicting the recurrence risk of a gastric cancer patient after treatment and application of the sugar chain marker combination. The invention discovers that the levels of six specific N-sugar chains (NGA2F, NG1A2F, NA3, NA3Fb, NA4 and NA4Fb) in blood are obviously related to relapse during definite diagnosis of gastric cancer for the first time. On the basis, a gastric cancer recurrence risk prediction model GC-GPSS is constructed through Cox regression. According to the model, individual risk scores are calculated by using a quantification formula containing a fixed regression coefficient (beta), and patients are divided into a high-risk group and a low-risk group according to a preset threshold. A verification result shows that the model can effectively distinguish patient groups with different recurrence risks. The marker combination, the prediction model and the system provided by the invention provide a brand new tool for realizing earlier and more objective recurrence risk assessment in the early stage of gastric cancer diagnosis and treatment, and have important clinical application value.

The invention discloses an antibacterial peptide PA targeting multi-drug-resistant gram-negative bacteria and application of the antibacterial peptide PA, and the amino acid sequence of the antibacterial peptide PA is shown as SEQ ID NO.1. The antibacterial peptide PA provided by the invention has a remarkable antibacterial effect of the multi-drug-resistant gram-negative bacteria, is quick in bactericidal effect, does not have hemolysis and cytotoxicity, does not cause renal toxicity after treatment, and can be used for preparing the antibacterial peptide PA for treating the multi-drug-resistant gram-negative bacteria. The biological safety is good, and the compound can be used for treating bacterial infection and can also be applied to other scenes needing sterilization or bacterial growth inhibition.

The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods.

A prediction system includes: a terminal; and a processor, communicatively coupled to the processor. The processor is configured to: acquire medical treatment information including images captured at at least one of before, during, immediately after, and after a predetermined period from treatment of a patient with a symptom of a vascular disease; classify a condition of the patient based on a classification image; learn the medical treatment information in association with the condition of the patient; and predict at least one of a treatment effect and a prognosis when treatment intervention is performed for the patient based on a learning result.

This reduces the difference in the relative positional relationship between the ultrasound probe and the object being treated before and after treatment on the subject. [Solution] The ultrasonic probe 16a is marked with a probe detection mark 20, and the object to be treated T is marked with an object detection mark 22. The pre-treatment relative relationship calculation unit 48 calculates the pre-treatment relative relationship between the ultrasonic probe 16a and the object to be treated T during pre-treatment ultrasonic transmission and reception, based on a pre-treatment camera image that includes images of the probe detection mark 20 and the object detection mark 22 formed on the object to be treated T before treatment. The current relative relationship calculation unit 50 calculates the current relative relationship between the ultrasonic probe 16a and the object to be treated T, based on a current camera image that includes images of the probe detection mark 20 and the object detection mark 22 formed at the present time. The probe control support unit 52 performs control to bring the current relative relationship closer to the pre-treatment relative relationship.

The invention relates to the field of wastewater treatment, in particular to an ozone microbubble and ultraviolet combined flotation tail water treatment method and device. The method comprises the following steps: flotation tail water continuously enters a treatment device from the bottom, high-concentration ozone generates micro-nano bubbles through a microporous aeration head at the bottom of the treatment device, the micro-nano bubbles are mixed with the flotation tail water in a turbulent flow manner, and the flotation tail water with gas and liquid fully mixed continuously rises to gradually submerge an ultraviolet generation tube arranged in the treatment device and above the microporous aeration head; the ultraviolet generating tube emits ultraviolet light to treat flotation tail water mixed with micro-nano bubbles, the treated water is discharged from one side of the top of the treatment device, and residual gas is discharged from an exhaust port of the treatment device. The oxidation efficiency is remarkably improved, the contact time is prolonged, the ozone mass transfer efficiency and the pollutant removal rate are improved, meanwhile, direct contact between the ultraviolet lamp and water is isolated, the problem of scaling of the ultraviolet lamp is effectively solved, the service life of the device is prolonged, and the treatment effect is improved.

The invention discloses a control method and device and an ultrasonic therapeutic apparatus, and the method comprises the steps: firstly obtaining the positions of a plurality of treatment points in a target region, then controlling a treatment handle to treat the target region at the plurality of treatment points, scanning the target region after the treatment of the target region is completed, and obtaining the image data of the target region, the image data is displayed on the display, so that a user can observe the target area after a round of treatment, the current treatment effect of the target area is judged, and then the treatment handle is controlled to treat the target treatment point again when the treatment effect of the target treatment point is determined not to reach the preset threshold value based on the image data; therefore, evaluation while treatment is realized, the area which does not reach the preset standard can be accurately positioned, the area is treated again, and the reliability and the treatment efficiency of single treatment are improved.

The utility model relates to a kind of reverse osmosis thick water emission reduction and reuse system, belong to water treatment technical field.The system includes the thick water reverse osmosis booster pump, ultra-low pressure thick water reverse osmosis device connected in turn, reuse water tank, wherein, reverse osmosis thick water is treated by preposed reverse osmosis device, and after being added hydrochloric acid and scale inhibitor by hydrochloric acid dosing device, scale inhibitor dosing device to reverse osmosis thick water, it is entered ultra-low pressure thick water reverse osmosis device by thick water reverse osmosis booster pump after treatment;The thick water generated after ultra-low pressure thick water reverse osmosis device treatment is directly discharged, and water production enters reuse water tank, part is reused, another part is washed to ultra-low pressure thick water reverse osmosis device by flushing water pump;While ultra-low pressure thick water reverse osmosis device is connected chemical cleaning device.The utility model has the advantages of flexible system operation mode, simple operation, high degree of automation, efficient energy saving, low operating cost, stable and reliable etc..

This invention discloses an antimicrobial peptide PA targeting multidrug-resistant Gram-negative bacteria and its application. The amino acid sequence of the antimicrobial peptide PA is shown in SEQ ID NO.1. The antimicrobial peptide PA provided by this invention has a significant antibacterial effect against multidrug-resistant Gram-negative bacteria, and has a rapid bactericidal onset, no hemolysis or cytotoxicity, does not cause nephrotoxicity after treatment, and has good biosafety. It can be used for the treatment of bacterial infections and can also be applied to other scenarios that require bactericidal or antibacterial growth inhibition.

The invention provides application of an SNP (Single Nucleotide Polymorphism) marker of MIA2 in predicting the curative effect of an antithrombotic drug on thrombus, and belongs to the fields of molecular biology and cardiovascular medicine. According to the application disclosed by the invention, one or more of rs11845046 and rs10134365 of the MIA2 gene is found to be related to the prediction of the curative effect of dabigatran on thrombus for the first time. Gene polymorphism analysis and an ROC curve verify that the curative effect of an NVAF patient after the NVAF patient is treated by using the antithrombotic drug is related to the genotypes of rs11845046 and rs10134365 of the MIA2 gene in a patient sample, and when the genotype of the rs11845046 is GG or the genotype of the rs10134365 is CC, the drug effect of the subject taking the antithrombotic drug is good but the probability of bleeding events is increased.

This application relates to the field of functional composition technology, and in particular to a GABA-vitamin D neuroprotective composition and its preparation method, comprising medium-chain triglycerides, modified phospholipids, and a GABA-vitamin D blend. This application utilizes the low interfacial tension and strong amphiphilic compatibility of medium-chain triglycerides and modified phospholipids, enabling them to be miscible with the blend, thus improving the characteristics of GABA and vitamin D being easily degraded and oxidatively inactivated under complex physiological environments, and solving the problems of poor stability and asynchronous absorption. In the preparation method, the preferred component mass ratio is (0.6–1.5):1:(1–1.6), and mixing is carried out at 50–80°C for 10–60 min. The resulting system features high encapsulation efficiency, uniform particle size distribution, and high bioavailability. After treatment in simulated gastric fluid (pH 1.2) for 2 hours, the average GABA retention rate is ≥88% (optimal up to 94.3%), and the average vitamin D retention rate is ≥94% (optimal up to 96.8%). After treatment in simulated intestinal fluid (pH 6.8) for 4 hours, the simultaneous release rate of GABA and vitamin D is ≥90%, achieving precise intestinal delivery and making it suitable for industrial production.

The application relates to the field of spray towers, in particular to a tail gas treatment equipment for leftover material recycling production line, which comprises a tower body, the tower body is a core bearing structure for tail gas treatment; an air outlet pipe and an air inlet pipe are fixedly installed on the outer side of the tower body respectively, the air inlet pipe is located below the air outlet pipe, tail gas enters the tower body through the air inlet pipe and is discharged from the air outlet pipe after treatment; a first liquid outlet and a second liquid outlet are formed in the outer side of the tower body respectively, the second liquid outlet is located below the first liquid outlet and is used for discharging waste liquid after spraying in the tower; a flow guide mechanism is arranged on the outer side of the tower body and is used for guiding the tail gas below the tower body to the upper side, so that directional conveying of the tail gas is realized; the tail gas treatment equipment for the leftover material recycling production line can rotate and stir under the action of airflow, the gas-liquid mixing uniformity is improved, and efficient degradation and interception are realized.

The present application belongs to the technical field of alloy surface treatment, and discloses a method for removing surface electric erosion pits of CoCrWNi alloy wire. The electrolyte is prepared from phosphoric acid, sulfuric acid, water and glycerol; the wire is used as an anode, and electrolytic polishing is carried out at a temperature of 60 DEG C and a voltage of 11 V for 2 min 30 s; and after polishing, deacidification, neutralization and drying passivation treatment are sequentially carried out. By adding glycerol and controlling the "high-temperature fast polishing" window, the method can selectively flatten the flange of the electric erosion pit and fill the pit bottom by using the anode selective dissolution and viscous film leveling mechanism, effectively removes the electric erosion pits with a depth of microns to tens of microns, and avoids over-corrosion of the substrate, so that the surface of the wire after treatment is mirror-like and glossy, without pitting and shadow, and the fatigue life and use safety of the wire are significantly improved.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The application relates to an intelligent temperature control moisturizing skin protection device for tumor radiotherapy patients, which comprises an intelligent humidifier body, a telescopic pipe fixedly connected to a liquid outlet of the intelligent humidifier body, a supporting bottom plate, a bearing disc rotatably connected to the surface of the supporting bottom plate, a cross trajectory groove and at least one radial hole formed in the bearing disc, the intelligent humidifier body arranged on the bearing disc, a transmission structure arranged in the supporting bottom plate and an auxiliary structure. The driving member drives the rotating column to continuously rotate, and a set of connecting rod mechanisms are used to convert the rotating motion into specific sector reciprocating swing of the contact wheel, the contact wheel drives the cross trajectory groove on the bearing disc, and finally drives the bearing disc and the intelligent humidifier on the bearing disc to intermittently rotate, so that the output of the moisturizing medium is no longer limited to before and after treatment, but can be continuously carried out during a single treatment lasting for dozens of minutes, and real-time and active protection of the skin is realized.

The utility model discloses a purification adsorption box for removing formaldehyde from plates, which comprises an adsorption box, a heating box and a driving motor, a plurality of support plates for supporting the plates are fixedly mounted on two sides of an inner cavity of the adsorption box along the vertical direction, the heating box is fixedly mounted at the top of the adsorption box, and a heating coil is fixedly mounted in the inner cavity of the adsorption box. A heat conduction pipe communicated with an inner cavity of the adsorption box is fixedly installed at the top of the adsorption box, the end, away from the heating box, of the heat conduction pipe extends to the position right behind the adsorption box, a plurality of guide pipes are fixedly installed on the outer wall of the heat conduction pipe, and a plurality of installation holes matched with the guide pipes are formed in the outer wall, away from the open end of the adsorption box, of the adsorption box in the vertical direction. The ends, away from the heat conduction pipe, of the multiple guide pipes are inserted into inner cavities of the mounting holes. According to the utility model, through the mutual cooperation of all the components, the volatilization efficiency of formaldehyde in the plate can be effectively improved, and the content of formaldehyde in the treated plate is further reduced.

The invention relates to the technical field of medical data processing, and discloses a cancer immunotherapy prognosis prediction method, system and equipment based on CD8 + T cell density in a necrotic area and a medium. The method comprises the following steps: firstly, extracting pathological features on a CD8 immunohistochemical staining (IHC) slice image of tumor tissue of a to-be-detected person after neoadjuvant immunotherapy by using a multi-scale feature extraction model, and then carrying out regional division on the CD8 IHC slice image by using a regional classification model to obtain a necrotic region; then, the CD8 + T cells in the necrotic area are recognized and counted through the target recognition model, the cell density of the CD8 + T cells in the necrotic area is rapidly obtained, and finally, the EFS of the person to be detected is accurately predicted based on the cell density of the CD8 + T cells in the necrotic area. According to the method, efficient and high-precision EFS prediction can be carried out only through the CD8IHC slice image of the tumor tissue, and a doctor can make a proper diagnosis and treatment plan for a patient according to a prediction result.

The invention discloses a risk score prediction curve of objective remission rate (ORR), disease control rate (DCR), progression-free lifetime (PFS) and total lifetime (OS) of a patient with advanced gastric or gastroesophageal junction adenocarcinoma after first-line chemotherapy and immunotherapy based on clinical inflammation indexes and application of the risk score prediction curve. The risk score is established based on clinical inflammation indexes and used for drawing a prediction curve of PFS and OS after first-line chemotherapy and immunotherapy and ORR and DCR, common inflammation-related laboratory indexes are integrated, the calculation method is simple, and clinical doctors and patients can conveniently operate to predict ORR, DCR, PFS and OS after treatment. Meanwhile, the risk score prediction model can provide certain help for selection of treatment schemes of later gastric or gastroesophageal junction adenocarcinoma patients in the future.

The application relates to a pain real-time discrimination and treatment effect evaluation system based on EEG microstate monitoring. The system comprises the following modules: a microstate extraction and analysis module which extracts GFP peak topography from EEG signal data, optimizes a template map, calculates the average duration of each microstate category and the like, and outputs a microstate feature parameter set; a pain real-time discrimination module which inputs the microstate feature parameter set into a deep learning model for detection to obtain a detection result containing a pain level; and a treatment effect evaluation module which obtains and compares the microstate feature parameter set before and after treatment, obtains a quantitative treatment effect index, and generates a report containing the index, analysis results and a microstate change trend chart. The system can monitor the pain state of a patient in real time through EEG signal microstate, and can provide objective evaluation indexes about the treatment effect for a clinician by quantifying the dynamic change of the EEG microstate of the patient before and after treatment, so that the scientificity and accuracy of treatment effect monitoring are improved.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, "treatment" generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

This invention provides a water quality monitoring method for treated water that confirms that the treated water, after coagulation and sedimentation treatment of COD / phosphorus / nitrogen / cyanide in collected dust (raw water), meets water quality standards, predicts deterioration in treatment efficiency during coagulation and sedimentation treatment, enables early detection of abnormal water, and facilitates rapid response to abnormal water. [Solution] A water quality monitoring method for treated water, comprising: a measurement step for automatically measuring the amount of COD / phosphorus / nitrogen / cyanide in treated water; a coagulation-sedimentation step for obtaining treated water by circulating raw water containing coagulated material including copper, iron, etc., and performing mixing, coagulation, and sedimentation treatment in that order; a sampling and analysis step for collecting an analytical sample, in which a portion of the raw water in a mixing tank is intermittently separated while it is circulating, a portion of the separated raw water is injected under pressure into the cylinder of a cylindrical ceramic filter which is a porous material, a portion of the filtered water obtained is taken out, and the filtered water is automatically introduced into an analytical device as an analytical sample for measuring the amount of nitrogen, etc. in the raw water, and the amount of nitrogen, etc. in the sample is automatically measured; and a control step for controlling the operating conditions of the coagulation-sedimentation step using the measured values ​​obtained in the analysis step.

The invention discloses a device and a method for rapidly degrading antibiotics through plasma generated by microwave discharge in a liquid phase. The device comprises a liquid path conveying system, a microwave energy transmission discharging system, a reactor and a gas path control and liquid control system. The liquid path system sends antibiotic wastewater to be degraded to the reactor, the microwave system generates plasmas through discharging, the reactor degrades the wastewater through the plasmas, and the gas path and liquid outlet system regulates and controls degraded gas and water discharge after treatment. The device depends on a liquid-phase microwave discharge technology and has broad-spectrum degradation capacity. A high-temperature and high-pressure environment and an exogenous chemical reagent are not needed, instantaneous breakdown and deep mineralization of wastewater can be realized, and the problems of slow reaction, strong selectivity and easy secondary pollution of a traditional method are solved. The reactor can concentrate microwave energy, a treatment blind area is eliminated, a gas path and a liquid outlet system guarantee controllable discharge, and the service life of equipment is prolonged. The device is driven by electric energy in the whole process, is flexible to operate and provides a green and efficient technical path for antibiotic wastewater treatment.

The present application relates to the technical field of vascular interventional treatment instruments, and discloses a system and method for the selective laser ablation of restenosis after the treatment of Budd-Chiari syndrome, comprising a controller, a pulse emission module and a reference element built into a catheter, the system is based on the reference element for periodic self-calibration, collects and processes the associated photoacoustic signals to identify the tissue type, and then realizes the selective ablation of the diseased tissue and the boundary self-stop when the healthy tissue is touched. The present application converts the traditional open-loop energy delivery into a closed-loop self-control process with real-time information interaction capability, so that the ablation operation end can in-situ perceive the tissue boundary and realize autonomous stop, thereby avoiding the problem of damaging the healthy tissue due to uncontrollable energy application, improving the safety of the operation, and having the advantages of high precision, few complications, repeatable treatment and the like.

The invention discloses a proton treatment plan verification and optimization device and method and related equipment, and relates to the technical field of radiotherapy. The device comprises an image acquisition module which is used for acquiring a PET image of a patient after completing at least one proton treatment irradiation; the dose prediction module is used for mapping the treated PET image into actual deposited dose distribution in the body of the patient based on the trained generative model so as to predict actual distribution dose distribution; and the adjustment and optimization module is used for generating an adjusted fractional treatment plan when the deviation between the predicted actual distribution dose distribution and the initial planned dose distribution is greater than a deviation threshold value. Based on in-vivo measurement information, the actual deposition dose is accurately verified and dynamically optimized, and accurate and safe proton therapy is achieved.

A cancer immunotherapy for treating cancers such as melanoma is presented. A method for treating cancer in a subject via administration of anti-LY6E antibody to the subject. The method can further include administering an IFNAR blockade to inhibit type-1 interferon (IFN) signaling, thereby enhancing the ant-tumoral cytotoxic activity of T cells. The IFNAR can include anti-IFNα. The method can also include administering anti-PD1 antibody prior to, commensurate, or after treatment with anti-LY6E. A composition for treating cancer and modulating immune responses in a subject is also included. The composition can include, among other things, the anti-LY6E antibody, the IFNAR blockade, and anti-PD1. The composition and method also present a mechanism to modulate immune response in a subject by preventing upregulation of a Ly6ahigh T-cell subpopulation in response to a stimulus such as cancer, UVB, or interferons.

The invention discloses an application of a natural product WithangatinA in preparation of erythroleukemia induced differentiation treatment drugs, the natural product WithangatinA promotes HEL and K562 cells to be transformed from malignant proliferative cells to normal megakaryocytes by inducing the cell particle size to become larger and significantly increasing multinuclear megakaryocytes and promoting expression of surface labeled molecules differentiated from megakaryocytes at the same time, and the erythroleukemia induced differentiation treatment drugs are obtained. The effect of resisting erythroleukemia is achieved. After the natural product Withangulin A is adopted for treatment, the size and the weight of the spleen of a leukemia mouse can be remarkably reduced, the hematocrit and the platelet number of the mouse are remarkably increased, in addition, treatment of the natural product Withangulin A has no obvious influence on the weight of the mouse, and the safety is high. In-vivo research shows that the medicine can induce megakaryocyte differentiation of erythroleukemia in a mouse body, the effect of resisting erythroleukemia is achieved, and a research basis is provided for development of differentiation treatment medicines of erythroleukemia.